Business
AIM Rule 17 and Schedule 2(g) Update
AIM Rule 17 and Schedule 2(g) Update.
About this update from Hvivo Plc
[{"type":"text","content":"\n\n\nhVIVO plc\n(\"hVIVO\", the \"Company\" or the \"Group\")\n \nAIM Rule 17 and Schedule 2(g) Update\n \nhVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the following update in relation to directors' disclosure for Martin Gouldstone, Non-Executive Director of the Company, pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.\n \nOncimmune Holdings plc, a company of which Martin Gouldstone is CEO, was placed into administration on 26 March 2025.\n \nFor further information please contact:\n \n\n\n\n\nhVIVO plc\n\n\n+44 (0)20 7756 1300\n\n\n\n\nYamin 'Mo' Khan, Chief Executive Officer\nStephen Pinkerton, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCavendish Capital Markets Limited (Nominated Adviser and Joint Broker)\n\n\n+44 (0)20 7220 0500\n\n\n\n\nGeoff Nash, Camilla Hume, Harriet Ward\nNigel Birks - Life Science Specialist Sales\nLouise Talbot - Sales\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP (Joint Broker)\n\n\n+44 (0)20 7418 8900\n\n\n\n\nJames Steel, Dr Christopher Golden\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDavy (Joint Broker)\n\n\n+353 (0) 1 679 6363\n\n\n\n\nAnthony Farrell, Niall Gilchrist\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR (Financial PR & IR)\nPaul McManus / Phillip Marriage /\nLouis Ashe-Jepson\n\n\n+44 (0)20 7933 8780 or [email protected]\n+44 (0)7980 541 893 / +44 (0)7867 984 082 /\n+44 (0)7747 515 393\n\n\n\n\n\n\n\n\n\n\n\n \n\n \nNotes to Editors\n \nhVIVO plc (Ticker: HVO) is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.\n \nhVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.\n \nThrough its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, inc...